Healthcare Industry News: Novation
News Release - June 4, 2007
Abbott Signs Agreement With Novation for Diagnostic Equipment and TestsABBOTT PARK, Ill., June 4 (HSMN NewsFeed) -- Abbott (NYSE: ABT ) announced today that it has signed a new group purchasing agreement with Novation, LLC, the health care contracting services company of VHA Inc., and the University HealthSystem Consortium, two national health care alliances, for a broad line of the company's diagnostic equipment.
The three-year contract covers all of Abbott's immunochemistry analyzers, reagents and accessories, as well as the ARCHITECT® ci8200 and ci16200.
Abbott also will work with Novation, LLC to help with laboratory automation, which may assist alliance member hospitals in delivering quality lab results while maximizing resources.
The contract represents potential sales to Novation alliance members in excess of $350 million in supplies over three years.
"Abbott has a strong presence in immunoassay testing. Our ARCHITECT® platforms promote integrated platforms to the hospital market and bring advantages to the customer," said Larry Pitts, divisional vice president, Abbott Diagnostics. "Abbott has a longstanding relationship with Novation and we look forward to partnering with them further in the future."
"Novation is pleased to offer VHA and UHC members a complete offering of immunochemistry testing," said Sherry Dobis, director, contract services, Novation.
Novation is the industry's leading health care contracting services company that delivers unmatched savings to nearly 2,500 members and affiliates of VHA Inc. and the University HealthSystem Consortium. By combining scale and agility with clinical knowledge and product expertise, Novation offers the most extensive range of innovative contracting services. VHA and UHC members used Novation contracts to purchase more than $30 billion in supplies in 2006. For more information, visit www.novationco.com.
About Abbott Diagnostics
Abbott Diagnostics is a global leader in in vitro diagnostics and offers a broad range of innovative instrument systems and tests for hospitals, reference labs, blood banks, physician offices and clinics. With more than 69,000 institutional customers in more than 100 countries, Abbott's diagnostic products offer customers automation, convenience, cost effectiveness and flexibility. Abbott has helped transform the practice of medical diagnostics from an art to a science through the company's commitment to improving patient care and lowering overall costs. The history of Abbott Diagnostics is filled with examples of first-of-a-kind products and significant technological advancements.
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.
Abbott's news releases and other information are available on the company's Web site at www.abbott.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsAbbott's XIENCE Stent Receives FDA Approval for Shortest Blood Thinner Course for High Bleeding Risk Patients
Abbott Confirms Capacity to Support Expanded Use of HeartMate 3(TM) Heart Pump
Abbott Receives CE Mark for Navitor(TM), the Latest-Generation Transcatheter Aortic Valve Implantation (TAVI) System to Treat Aortic Stenosis